Director, Medical Affairs - Immunology

Director, Medical Affairs – Immunology

new script to outmatch disease.

Nurix Therapeutics is seeking a Director, Medical Affairs – Immunology to lead medical strategy and execution for the company's Phase 2 immunology and inflammation (I&I) assets, with initial focus on bexobrutideg (NX-5948), an oral BTK degrader advancing into Phase 2 development in chronic spontaneous urticaria (CSU) and Multiple Sclerosis (MS) as part of Nurix's global collaboration with Roche. This role owns the tactical medical affairs plan for the CSU and MS Phase 2 programs end-to-end — from advisory input and KOL engagement through investigator relationships, field medical guidance, and evidence generation planning — and will expand scope as additional I&I assets advance through Phase 2.

Reporting to the Head of Medical Affairs, I&I, this leader will operate as the day-to-day scientific and strategic lead for the CSU and MS indications, translating emerging clinical and mechanism-of-action data into credible medical narratives for allergists, immunologists, dermatologists, neurologists and academic investigators. The role partners closely with Hematology, Clinical Development, Clinical Operations, HEOR, Regulatory, Legal, Compliance, and Nurix's co-development partner Roche to ensure medical activities are aligned with the development plan and conducted compliantly.

• Own and execute the Medical Affairs tactical plan for bexobrutideg in CSU and MS, including medical messaging, advisory boards, congress strategy, publication planning, and scientific engagement priorities, in partnership with the Head of Medical Affairs, I&I.
• Translate Phase 1/2 clinical and translational data (e.g., BTK degradation, FcεRI-driven biology) into clear, credible medical narratives for external and internal audiences.
• Provide Medical guidance to the Field Medical team supporting the Immunology Pipeline including education priorities, scientific training, and KOL engagement objectives.
• Build relationships with select key opinion leaders, allergists, immunologists, dermatologists, neurologists and academic investigators relevant to CSU, MS and the broader I&I portfolio.
• Support investigator identification, site engagement, and treatment-center collaboration to inform Phase 2 trial site selection and enrollment planning.
• Lead or co‑lead advisory boards, investigator meetings, and congress activities (e.g., AAAAI) to gather external input and inform development and evidence generation priorities.
• Partner with Hematology, HEOR and Clinical Development on evidence generation planning to address stakeholder and future payer needs as the pipeline programs mature.
• Collaborate with External medical affairs counterparts to ensure aligned scientific messaging and engagement strategy under the co‑development agreement.
• Partner with Regulatory, Legal, and Compliance to ensure all medical affairs activities are conducted within regulatory and compliance guardrails.
• Monitor the CSU, MS and broader I&I competitive and scientific landscape, translating insights into medical strategy recommendations.
• Contribute to the build‑out of Medical Affairs infrastructure (SOPs, MLR processes, medical information) as the I&I function scales.

• MD, PharmD, PhD, or DO required.
• 8+ years of biopharmaceutical Medical Affairs and/or Field Medical experience, with direct experience supporting clinical development of Phase 2 (or Phase 1b/2) assets.
• Demonstrated experience in translating scientific data and HCP feedback into effective medical communication strategy.
• Experience in immunology, allergy/immunology, dermatology, or related inflammatory/autoimmune disease areas required; strong preference for a combination of neuroscience…